Swedish medical technology company SciBase has unveiled its new instrument, Nevisense View for early detection of malignant melanoma.

The device features the company’s patented electrical impedance spectroscopy (EIS) which offers visual information derived from the digital dermascopy to facilitate an improved and simplified diagnostic process.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The mechanism of the device uses electrical impulses to detect abnormal cell structures indicative of malignant melanoma.

"The use of EIS can reduce the number of cases that need to be followed up using SDDI by almost half."

Digital dermascopy creates visual evaluations of skin lesions' using a dermascope, as the short term digital dermoscopy imaging (SDDI) is leveraged in hard-to-diagnose cases to compare pictures of lesions which have undergone change with time.

SciBase’s Nevisense View simplifies the process of conducting skin examinations as it saves all data derived from the exam in the same instrument.

See Also:

Its ability to track the changes of a suspicious lesion, using EIS values and images, aids in preventing the unnecessary removal of benign tissue, and helps to avoid malignant melanoma going undetected during an examination.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The device is enabled with wireless transmission of images and is designed with easy-to-use follow-up functions with a shared screen to compare lesions over time.

SciBase CEO Simon Grant said: “According to a new study, conducted by researchers from Melanoma Institute of Australia and Royal Prince Alfred Hospital in Sydney, the use of EIS can reduce the number of cases that need to be followed up using SDDI by almost half, and may also allow for early detection of malignant melanoma three months earlier than traditional methods.”